Uterine Cancer: Adjuvant Therapy and Management of Metastatic Disease.

[1]  H. Putter,et al.  Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy , 2018, British Journal of Cancer.

[2]  T. Bosse,et al.  Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial. , 2018, Gynecologic oncology.

[3]  A. Stuckey,et al.  A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer. , 2018, Gynecologic oncology.

[4]  P. Pollock,et al.  Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative , 2018, Modern Pathology.

[5]  A. Talhouk,et al.  Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Marc J. Williams,et al.  Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response , 2018, The Journal of pathology.

[7]  H. Burris,et al.  A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors , 2018, Investigational New Drugs.

[8]  Donavan T. Cheng,et al.  The genetic landscape of endometrial clear cell carcinomas , 2017, The Journal of pathology.

[9]  J. Boggess,et al.  Sentinel lymph node mapping and staging in endometrial cancer: A Society of Gynecologic Oncology literature review with consensus recommendations. , 2017, Gynecologic oncology.

[10]  M. Munsell,et al.  A prospective validation study of sentinel lymph node mapping for high-risk endometrial cancer. , 2017, Gynecologic oncology.

[11]  Ludmila V. Danilova,et al.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.

[12]  A. Talhouk,et al.  Confirmation of ProMisE: A simple, genomics‐based clinical classifier for endometrial cancer , 2017, Cancer.

[13]  Yulei N. Wang,et al.  A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study) , 2016, Cancer.

[14]  A. Talhouk,et al.  Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. , 2016, Gynecologic oncology.

[15]  K. K. van de Vijver,et al.  L1CAM expression in endometrial carcinomas: an ENITEC collaboration study , 2016, British Journal of Cancer.

[16]  A. Weaver,et al.  Comparison of a sentinel lymph node and a selective lymphadenectomy algorithm in patients with endometrioid endometrial carcinoma and limited myometrial invasion. , 2016, Gynecologic oncology.

[17]  H. Mackay,et al.  Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer , 2016, Modern Pathology.

[18]  J. Ledermann,et al.  ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer , 2015, International Journal of Gynecologic Cancer.

[19]  M. Birrer,et al.  Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study. , 2015, Gynecologic oncology.

[20]  I. Vergote,et al.  Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. , 2015, Gynecologic oncology.

[21]  A. Talhouk,et al.  A clinically applicable molecular-based classification for endometrial cancers , 2015, British Journal of Cancer.

[22]  D. Lambrechts,et al.  Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer , 2014, Journal of the National Cancer Institute.

[23]  R. Rouzier,et al.  Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study. , 2015, Gynecologic oncology.

[24]  T. Bosse,et al.  L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results. , 2014, European journal of cancer.

[25]  M. Köbel,et al.  POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. , 2014, Gynecologic oncology.

[26]  T. Bosse,et al.  High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma. , 2014, Gynecologic oncology.

[27]  Mitsuaki Suzuki,et al.  Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study. , 2013, Gynecologic oncology.

[28]  P. Altevogt,et al.  L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. , 2013, Journal of the National Cancer Institute.

[29]  A. Secord,et al.  A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancer. , 2013, Gynecologic oncology.

[30]  Yin-hua Yu,et al.  Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer , 2011, Cancer science.

[31]  P. Zola,et al.  Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies. , 2010, European journal of cancer.

[32]  J. Berek,et al.  Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. , 2010, Gynecologic oncology.

[33]  V. Torri,et al.  Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. , 2009, Journal of the National Cancer Institute.

[34]  T. Luukkaala,et al.  Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. , 2008, Gynecologic oncology.

[35]  Nobuyuki Susumu,et al.  Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[36]  O. Olopade,et al.  An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. , 2008, Gynecologic oncology.

[37]  Meenakshi Singh,et al.  Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. , 2007, Gynecologic oncology.

[38]  G. Fleming,et al.  The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. , 2007, Gynecologic oncology.

[39]  J. Cooper,et al.  Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. , 2006, Gynecologic oncology.

[40]  P. Zola,et al.  Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial , 2006, British Journal of Cancer.

[41]  M. Maiman,et al.  A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study , 2004 .

[42]  J. Fiorica,et al.  Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. , 2004, Gynecologic oncology.

[43]  M. Piccart,et al.  Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.